Neuroprotective mechanisms of 3‑n‑butylphthalide in neurodegenerative diseases (Review)

Since 3-n-butylphthalide (NBP) was approved by the China Food and Drug Administration for the treatment of acute ischemia stroke in 2002, a number of studies have investigated NBP worldwide. In recent years, NBP has also demonstrated potential as treatment of several neurodegenerative diseases, whic...

Full description

Saved in:
Bibliographic Details
Published inBiomedical reports Vol. 11; no. 6; pp. 235 - 240
Main Authors Luo, Rixin, Wangqin, Runqi, Zhu, Lihong, Bi, Wei
Format Journal Article
LanguageEnglish
Published Athens Spandidos Publications 01.12.2019
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Since 3-n-butylphthalide (NBP) was approved by the China Food and Drug Administration for the treatment of acute ischemia stroke in 2002, a number of studies have investigated NBP worldwide. In recent years, NBP has also demonstrated potential as treatment of several neurodegenerative diseases, which has increased the interest in its mechanisms of protection and action. Clinical studies and studies that used cell or animal models, have directly demonstrated neuroprotective effects of NBP via the following mechanisms: i) Inhibiting the inflammatory reaction; ii) reducing mitochondrial oxidative stress; iii) regulating apoptosis and autophagy; iv) inducing resistance to endoplasmic reticulum stress; and v) decreasing abnormal protein deposition. Therefore, NBP may be a potential drug for neurodegenerative diseases, and it is particularly important to identify the mechanism of NBP as it may assist with the development of new drugs for neurodegeneration. The present review summarizes the neuroprotective mechanisms of NBP and discusses new perspectives and prospects. The aim of the current review is to provide a new summary regarding NBP and its associated mechanisms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Dr Wei Bi, Department of Neurology, The First Affiliated Hospital of Jinan University, 613 Huang Pu Street, Guangzhou, Guangdong 510632, P.R. China biwei4762@sina.com
ISSN:2049-9434
2049-9442
DOI:10.3892/br.2019.1246